Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Meropenem trihydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Meropenem belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections. Meropenem is used to treat the following infections in adults and children aged 3 months and older:
2.
e Meropenem
Do not use Meropenem if:
If you notice unexplained muscle pain, tenderness or weakness and/or dark coloured urine tell your doctor immediately. This may be a sign of muscle breakdown (called rhabdomyolysis) which may lead to kidney problems. If you are not sure if any of the above apply to you, talk to your doctor or nurse before using Meropenem. Liver problems If you notice yellowing of the skin and eyes, itchy skin, dark-coloured urine or light-coloured stool tell your doctor. This may be a sign of liver problems which your doctor needs to check. Other medicines and Meropenem Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because Meropenem can affect the way some medicines work and some medicines can affect the way Meropenem works. In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines: • Probenecid (used to treat gout). • Valproic acid/sodium valproate/valpromide (used to treat epilepsy). Meropenem should not be used because it may decrease the effect of sodium valproate. • Anti-coagulants (used to treat or prevent blood clots) taken by mouth. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor for advice before using this medicine. It is preferable to avoid the use of Meropenem during pregnancy. Your doctor will decide whether you should use Meropenem. It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving Meropenem. Small amounts of this medicine may pass into the breast milk and it may affect the baby. Therefore, your doctor will decide whether you should use Meropenem while breast-feeding. Driving and using machines No studies on the effect on the ability to drive and use machines have been performed. Meropenem has been associated with headache and tingling or pricking skin (paraesthesia). Any of these side effects could affect your ability to drive or operate machines. Meropenem may cause involuntary muscle movements which may cause the person's body to shake rapidly and uncontrollably (convulsions). This is usually accompanied with a loss of consciousness. Do not drive or use machines if you experience this side effect. Meropenem contains sodium Meropenem 500mg: This medicine contains approximately 45 mg of sodium (main component of cooking/table salt) in each 500 mg dose. This is equivalent to 2.25% of the recommended maximum daily dietary intake of sodium for an adult. Meropenem 1g: This medicine contains approximately 90 mg of sodium (main component of cooking/table salt) in each 1.0 g dose. This is equivalent to 4.5% of the recommended maximum daily dietary intake of sodium for an adult. If you have a condition which requires you to monitor your sodium intake, please inform your doctor, pharmacist or nurse. 3.
How to use Meropenem
Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with them if you are not sure. Use in adults
Use in children and adolescents
Meropenem.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Severe allergic reactions If you have any of these signs and symptoms, tell your doctor or nurse straight away. You may need urgent medical treatment. The signs and symptoms may include a sudden onset of:
Meropenem
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the container. The expiry date refers to the last day of that month. Do not store above 30°C. Do not freeze the reconstituted solution. Your doctor, pharmacist and nurse will know how to store this medicine. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. 6.
What Meropenem contains
The active substance is meropenem. Each vial contains 500 mg anhydrous meropenem as meropenem trihydrate. The active substance is meropenem. Each vial contains 1 g anhydrous meropenem as meropenem trihydrate. The other ingredient is anhydrous sodium carbonate. What Meropenem looks like and contents of the pack Meropenem is a white to light yellow powder in a vial with grey, bromobutyl rubber stopper sealed with a violet colour aluminium flip-off cap for the 500 mg and grey colour for 1g strength. Pack size: 10 vials. Marketing Authorisation Holder ACS Dobfar S.p.A. Viale Addetta 4/12, 20067 Tribiano (MI), Italy Manufacturer ACS Dobfar SpA Nucleo Industriale S. Atto, S. Nicolò a Tordino, 64100 Teramo,Italy Advice/medical education Antibiotics are used to treat infections caused by bacteria. They have no effect against infections caused by viruses. Sometimes an infection caused by bacteria does not respond to a course of an antibiotic. One of the commonest reasons for this to occur is because the bacteria causing the infection are resistant to the antibiotic that is being taken. This means that they can survive and even multiply despite the antibiotic. Bacteria can become resistant to antibiotics for many reasons. Using antibiotics carefully can help to reduce the chance of bacteria becoming resistant to them. When your doctor prescribes a course of an antibiotic it is intended to treat only your current illness. Paying attention to the following advice will help prevent the emergence of resistant bacteria that could stop the antibiotic working. 1. 2. 3. 4. 5.
It is very important that you take the antibiotic at the right dose, at the right times and for the right number of days. Read the instructions on the label and if you do not understand anything ask your doctor or pharmacist to explain. You should not take an antibiotic unless it has been prescribed specifically for you and you should use it only to treat the infection for which it was prescribed. You should not take antibiotics that have been prescribed for other people even if they had an infection that was similar to yours. You should not give antibiotics that were prescribed for you to other people. If you have any antibiotic left over when you have taken the course as directed by your doctor you should take the remainder to a pharmacy for appropriate disposal.
This leaflet was last revised in 02/2026.
The following information is intended for medical or healthcare professionals only: Intravenous bolus injection administration A solution for bolus injection is prepared by dissolving the drug product in water for injection to a final concentration of 50 mg/ml. Chemical and physical in-use stability for a prepared solution for bolus injection has been demonstrated for 3 hours at up to 25°C or 12 hours under refrigerated conditions (2-8°C). Intravenous infusion administration A solution for infusion is prepared by dissolving the drug product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to a final concentration of 1 to 20 mg/ml. Chemical and physical in-use stability for a prepared solution for infusion using 0.9% sodium chloride solution has been demonstrated for 6 hours at up to 25°C or 24 hours under refrigerated conditions (28°C). When Meropenem is dissolved in dextrose the solution should be used immediately From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately. If not used immediately in-use storage times and conditions are the responsibility of the user. Instructions for giving Meropenem to yourself or someone else at home Some patients, parents and carers are trained to give Meropenem at home. Warning – You should only give this medicine to yourself or someone else at home after a doctor or nurse has trained you.
Amount of 'Water for Injections' needed for reconstitution 10 ml 20 ml 30 ml 40 ml
Volume following reconstitution 10.5 ml 21 ml 31.3 ml 42 ml
Please note: If your prescribed dose of Meropenem is more than 1 g, you will need to use more than 1 vial of Meropenem. You can then draw the liquid in the vials into the one syringe. 6. Put the needle of the syringe through the centre of the grey rubber stopper and inject the recommended amount of Water for Injections into the vial or vials of Meropenem. 7. Remove the needle from the vial and shake the vial well for about 5 seconds or until all the powder has dissolved. Clean the grey rubber stopper once more with a new alcohol wipe and allow the rubber stopper to dry. 8. With the plunger of the syringe pushed fully into the syringe, put the needle back through the grey rubber stopper. You must then hold both the syringe and the vial and turn the vial upside down.
9. Keeping the end of the needle in the liquid, pull back the plunger and draw all the liquid in the vial into the syringe. 10. Remove the needle and syringe from the vial and throw the empty vial away in a safe place. 11. Hold the syringe upright, with the needle pointing upwards. Tap the syringe so that any bubbles in the liquid rise to the top of the syringe. 12. Remove any air in the syringe by gently pushing the plunger until all the air has gone. 13. If you are using Meropenem at home, dispose of any needles and infusion lines that you have used in an appropriate way. If your doctor decides to stop your treatment, dispose of any unused Meropenem in an appropriate way. Giving the injection You can either give this medicine through a short cannula or Venflon®, or through a port or central line. Giving Meropenem through a short cannula or Venflon® 1. Remove the needle from the syringe and throw the needle away carefully in your sharps bin. 2. Wipe the end of the short cannula or Venflon® with an alcohol wipe and allow it to dry. Open the cap on your cannula and connect the syringe. 3. Slowly push the plunger of the syringe to give the antibiotic steadily over about 5 minutes. 4. Once you have finished giving the antibiotic and the syringe is empty, remove the syringe and use a flush as recommended by your doctor or nurse. 5. Close the cap of your cannula and carefully throw the syringe away in your sharps bin. Giving Meropenem through a port or central line 1. Remove the cap on the port or line, clean the end of the line with an alcohol wipe and allow it to dry. 2. Connect the syringe and slowly push the plunger on the syringe to give the antibiotic steadily over about 5 minutes. 3. Once you have finished giving the antibiotic, remove the syringe and use a flush as recommended by your doctor or nurse. 4. Place a new clean cap on your central line and carefully throw the syringe away in your sharps bin.
Meropenem 1g powder for solution for injection/infusion vials comes as injection containing 1g. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Meropenem 1g powder for solution for injection/infusion vials is meropenem trihydrate.
Medicines with the same active substance, strength and form include: Meronem IV 1g Powder for solution for injection or infusion, Meropenem 1 g Powder for Solution for Injection or Infusion, Meropenem 1 g powder for solution for injection or infusion. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Meropenem 1g powder for solution for injection/infusion vials, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Meropenem is indicated for the treatment of the following infections in adults and children aged 3 months and older (see sections 4.4 and 5.1):
• Severe pneumonia, including hospital and ventilator-associated pneumonia.
• Broncho-pulmonary infections in cystic fibrosis
• Complicated urinary tract infections
• Complicated intra-abdominal infections
• Intra- and post-partum infections
• Complicated skin and soft tissue infections
• Acute bacterial meningitis
Meropenem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection
Meropenem may be used in the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Posology
The tables below provide general recommendations for dosing.
The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.
A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp.), or very severe infections.
Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).
Adults and Adolescents
Infection
Dose to be administered every 8 hours
Severe pneumonia including hospital and ventilator-associated pneumonia.
Broncho-pulmonary infections in cystic fibrosis
Complicated urinary tract infections
Complicated intra-abdominal infections
Intra- and post-partum infections
Complicated skin and soft tissue infections
Acute bacterial meningitis
Management of febrile neutropenic patients
500 mg or 1 g
2 g
500 mg or 1 g
500 mg or 1 g
500 mg or 1 g
500 mg or 1 g
2 g
1 g
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3 and 6.6).
Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.
Renal impairment
The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the administration of these dose adjustments for a unit dose of 2 g.
Creatinine clearance (ml/min)
Dose(based on “unit” dose range of 500 mg or 1 g or 2 g, see table above)
Frequency
26-50
10-25
<10
one unit dose
half of one unit dose
half of one unit dose
every 12 hours
every 12 hours
every 24 hours
Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.
There are no established dose recommendations for patients receiving peritoneal dialysis.
Hepatic impairment
No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).
Dose in elderly patients
No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.
Paediatric population
Children under 3 months of age
The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2).
Children from 3 months to 11 years of age and up to 50 kg body weight
The recommended dose regimens are shown in the table below:
Infection
Dose to be administered every 8 hours
Severe pneumonia including hospital and ventilator-associated pneumonia.
Broncho-pulmonary infections in cystic fibrosis
Complicated urinary tract infections
Complicated intra-abdominal infections
Complicated skin and soft tissue infections
Acute bacterial meningitis
Management of febrile neutropenic patients
10 or 20 mg/kg
40 mg/kg
10 or 20 mg/kg
10 or 20 mg/kg
10 or 20 mg/kg
40 mg/kg
20 mg/kg
Children over 50 kg body weight
The adult dose should be administered.
There is no experience in children with renal impairment.
Method of administration
Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3, and 6.6). Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.
For instructions on reconstitution of the medicinal product before administration, see section 6.6.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to any other carbapenem antibacterial agent.
Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of betalactam antibacterial agent (e.g. penicillins or cephalosporins).
The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.
Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. resistance
Resistance to penems of Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.
Hypersensitivity reactions
As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see sections 4.3 and 4.8).
Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.
If a severe allergic reaction occurs, the medicinal product should be discontinued and appropriate measures taken. Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem (see section 4.8). If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.
With other beta-lactam antibiotics there have been reports of hypersensitivity reaction which progressed to Kounis syndrome (acute allergic coronary arteriospasm that can result in myocardial infarction, see section 4.8)
Rhabdomyolysis
Rhabdomyolysis has been reported with the use of meropenem. If signs or symptoms of rhabdomyolysis are observed, meropenem should be discontinued and appropriate therapy initiated (see section 4.8).
Antibiotic-associated colitis
Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see section 4.8). Discontinuation of therapy with meropenem and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Seizures
Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see section 4.8).
Drug-induced liver injury (DILI) Hepatic function should be closely monitored during treatment with meropenem due to the risk of DILI (see section 4.8). If severe DILI occurs, treatment discontinuation should be considered as clinically appropriate. Meropenem should be reintroduced only if assessed as essential for treatment.
Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see section 4.2).
Direct antiglobulin test (Coombs test) seroconversion
A positive direct or indirect Coombs test may develop during treatment with meropenem.
Concomitant use with valproic acid/sodium valproate/valpromide
The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see section 4.5).
This medicinal product contains approximately90 mg sodium per 1 g vial, equivalent to 4.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
No specific medicinal product interaction studies other than probenecid were conducted.
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. Caution is required if probenecid is co-administered with meropenem.
The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.
Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60‑100 % decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid/sodium valproate/valpromide with carbapenem agents is not considered to be manageable and therefore should be avoided (see section 4.4).
Oral anti-coagulants
Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.
Paediatric population
Interaction studies have only been performed in adults.
Pregnancy
There are no or limited amount of data from the use of meropenem in pregnant women.
Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.
Breast-feeding
Small amounts of meropenem have been reported to be excreted in human milk. Meropenem should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.
No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesia and convulsions have been reported for meropenem.
Summary of the safety profile
In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3 %), rash (1.4 %), nausea/vomiting (1.4 %) and injection site inflammation (1.1 %). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6 %) and increased hepatic enzymes (1.5-4.3 %).
Tabulated risk of adverse reactions
In the table below all adverse reactions are listed by system organ class and frequency: very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Table 1
System Organ Class
Frequency
Event
Infections and infestations
Uncommon
oral and vaginal candidiasis
Blood and lymphatic system disorders
Common
thrombocythaemia
Uncommon
agranulocytosis, haemolytic anaemia thrombocytopenia, neutropenia, leucopenia, eosinophilia
Immune system disorders
Uncommon
anaphylaxis (see section 4.3 and 4.4), angioedema
Metabolism and nutrition disorders
Uncommon
Hypokalaemia
Psychiatric disorders
Rare
delirium
Nervous system disorders
Common
headache
Uncommon
paraesthesia
Rare
convulsions (see section 4.4)
Gastrointestinal disorders
Common
diarrhoea, abdominal pain, vomiting, nausea,
Uncommon
antibiotic-associated colitis (see section 4.4)
Hepatobiliary disorders
Common
transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased.
Uncommon
blood bilirubin increased, Drug-induced liver injury*
Skin and subcutaneous tissue disorders
Common
rash, pruritus
Uncommon
toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme (see section 4.4), urticaria.
Not known
drug reaction with eosinophilia and systemic symptoms, acute generalised exanthematous pustulosis (see section 4.4)
Musculoskeletal and connective tissue disorders
Not known
rhabdomyolysis
Renal and urinary disorders
Uncommon
blood creatinine increased, blood urea increased
General disorders and administration site conditions
Common
inflammation, pain
Uncommon
thrombophlebitis
pain at the injection site
*DILI includes hepatitis and liver failure
Description of selected avderse reactions
Kounis syndrome
Acute coronary syndrome associated with an allergic reaction (Kounis syndrome) has been reported with other beta-lactam antibiotics (see section 4.4)
Paediatric population
Meropenem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google Play or Apple App Store.
Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.
In individuals with normal renal function, rapid renal elimination will occur.
Haemodialysis will remove meropenem and its metabolite.
Ask anything about Meropenem 1g powder for solution for injection/infusion vials. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.